HEPATITIS C DRUG
Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India
Novartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, despite their India sales accounting for less than 0.5% of global revenues. Court submissions have highlighted development, clinical-trial and manufacturing costs against the medicines’ prices in India.
Doctors once told Pamela Anderson that she would live for only some more years, with cure rate of just 10%. ‘Took everything I had…'
Pamela Anderson recently reminisced about one of the most troubling periods in her life, when she was diagnosed with hepatitis C in the late 1990s. During that era, it was considered incurable. The Baywatch star admitted that her life was turned ‘inside out’ by the diagnosis, which was a ‘death sentence’ at that time. However, by 2015, she was cured.
World Hepatitis Day: Know about causes, symptoms and risk factors
July 28 is reserved to promote awareness of this insidious and deadly virus.
Cadila seeks nod to repurpose Hepatitis C drug for COVID-19 in India
India's Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.
Hepatitis C drugs may help fight COVID-19, supercomputer simulations suggest
Researchers from Johannes Gutenberg University Mainz (JGU) in Germany simulated the way that about 42,000 different substances listed in open databases bind to certain proteins of SARS-CoV-2, and thereby inhibit the penetration of the virus into the human body or its multiplication.
Johnson & Johnson arm halts R&D on Hepatitis C drug
Instead, the company will focus on a cure for chronic hepatitis B, an inflammation of the liver caused by a different virus.
- Go To Page 1

Hetero gets DCGI nod for generic chronic hepatitis C drug
The company "has received the approval for the generic version of 'Sofosbuvir+Velpatasvir' combination from the Drugs Controller General of India", Hetero said.

Patent not to affect hepatitis C drug price in India: Gilead Sciences Inc
"It is the company's goal to enable access to these medicines for as many people as possible, as quickly as possible," the spokesperson added.

Cipla, Emcure, Hetero and Natco Pharma join patent pool for new Hepatitis C drug Daclatavir
There might be more companies who might join the patent pool for the drug. Daclatasvir is known to cure multiple genotypes of the Hep C virus.

Desi generics firms pave way for cheaper hepatitis C drug
If scaling up of HIV treatment globally was made possible by Indian generics companies, it looks like they are set to repeat this feat with hepatitis C treatment too.

Hep C drugs will be a Rs 1,000-cr market; Cimivir-L will boost Biocon's virology biz: Kiran Mazumdar-Shaw
"The market for Hepatitis C drugs is fairly large. There are high incidences of Hepatitis C in many parts of our country."

Strides Shasun gets DCGI nod to manufacture Hepatitis C drug
Last year, Strides had entered into a licensing agreement with Gilead Sciences to bring Hepatitis C cure to 91 developing countries.

Cipla launches generic hepatitis C drug 'Hepcvir-L' in India
Cipla has launched generic tablets used for treating of hepatitis C under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 tablets in India.

New medicine for Hepatitis C treatment launched
During the conference, two new drugs were launched for treatment of Hepatitis C disease at affordable price.

Natco gets DCGI nod to launch hepatitis C drug in India
Natco Pharma has received approval from the Drugs Controller General of India (DCGI) to launch generic version of hepatitis C treatment drug in India.

Hetero receives drug controller approval for generic Daclatasvir
Daclatasvir in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent in India.

Hetero gets DCGI approval to market Hepatitis C drug
Hetero is the first company in India to receive the approval for the fixed-dose combination Ledipasvir-Sofosbuvir (90mg/400mg) from DCGI.

Roche cuts Hepatitis C drug cost by 65% for government institutions
Drug major Roche has reduced the prices of its Hepatitis C treatment drug 'Exxura' by 65 per cent across all government institutions in India.

Strides Arcolab launches generic version of Sofosbuvir
Strides Arcolab today announced launch of the generic version of Hepatitis C drug 'Sofosbuvir' under the brand name 'Virso'.

Cipla to launch generic Hepatitis C drug 'Hepcvir' in India
The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries, Cipla said.

Dr Reddy's shares up on Hepatitis C drug launch plan
Shares of Dr Reddy's Laboratories today settled with gains of nearly 2 per cent after the firm said it is planning to launch Hepatitis C drug in the country.

Dr Reddy's to launch Hepatitis C drug in India
Sofosbuvir is a medicine used for chronic Hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

Zydus Cadila launches Gilead's Hepatitis C drug in India
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

Natco Pharma ties up with Gilead Sciences for Hepatitis C drug
Natco was the only Indian generic drug maker that had filed a pre-grant patent opposition for the drug with the patent office.

Gilead's hepatitis C drug licensing to benefit more patients: Sitharaman
A delegation of Gilead Sciences Inc yesterday met Commerce and Industry Minister Nirmala Sitharaman and informed about the signing of non-exclusive licensing agreements.

Cure for Hepatitis C in HIV patients on the cards
Approximately one-third of HIV patients in the US have hepatitis C, with an estimated 7 million co-infected patients worldwide.

New drug combo cures toughest cases of hepatitis C
Results were similar in study participants infected with genotypes 2 or 3, strains which are less common in the US.
96,000 die every year due to Hepatitis C in India: Report
The report said the prevalence of Hepatitis C is estimated to be within 1.8-2.5 per cent, while among drug users it is 50-90 per cent.

IPAB's verdict on Roche's Hepatitis C drug patent may impact Merck
The IPAB revoked Roche's patent for Pegasys on grounds that the process of pegylation did not enhance the efficacy of the drug.
Load More